On June 2, Insilico Medicine fell 5.26% in regular trading, trading at HKD 37.48 per share, with trading volume of HKD 28.07 million. The stock has now accumulated a decline of nearly 40% over the past month.

On the news front, the company previously issued a voluntary announcement on May 27 explicitly clarifying that it currently has no definite plans for a secondary listing in Abu Dhabi. The market had previously anticipated that such a move would expand international financing channels and deepen the company's Middle East strategic presence, and the dashed expectation continues to suppress sentiment.

More critically, having listed on the Hong Kong exchange last December, the company has now formally entered its June lock-up expiry window. Shares held by cornerstone investors and employee stock option holders are approaching their release dates, intensifying market concerns over potential selling pressure. Additionally, the broader Hong Kong market faces a historic unlock wave in the second half of the year, with total cornerstone and pre-IPO investor share unlocks reaching HKD 780 billion, amplifying stock-level volatility.

Within the Life Sciences Tools and Services sector, all major peers declined, with Wuxi AppTec down 3.98%, Wuxi Biologics down 2.37%, XtalPi down 2.64%, GenScript Biotech down 2.30%, and Wuxi XDC down 2.40%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)